Sales Growth YoY (Last Twelve Months): Fulgent (FLGT)

NGS sequencing and cash for acquisitions are driving the growth of Fulgent Genetics, Inc. (FLGT). Revenues are based on cancer screenings and insurance reimbursement for tests. The brand is valued for its diagnostic accuracy and successful image transformation. The value 4.80 is the current value of the metric shown on the trailing twelve-month revenue change chart.
Fulgent Genetics, Inc. - analytical breakdowns and key metrics (FLGT)

This indicator tracks the rolling change in revenue over the last twelve months, neutralizing seasonal fluctuations to identify the true trajectory of business development. By analyzing the annual revenue growth dynamics over the TTM period, investors can see the scaling effect of the Fulgent Genetics, Inc. (FLGT) IT architecture, where bioinformatics automation converts increased order volumes into rapid profit growth by radically reducing unit costs.